HARMONY BIOSCIENCES HOLDINGS, INC. Research and Development Expense
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Research and Development Expense of $46.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. research and development expense for the quarter ending 2026-06-30 was $46.60M, a 7.10% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. research and development expense for the quarter ending 2026-03-31 was $69.38M, a 100.88% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. research and development expense for the quarter ending 2025-12-31 was $49.93M, a 44.04% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. research and development expense for the quarter ending 2025-09-30 was $54.96M, a 116.50% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. research and development expense for fiscal 2025 was $189.59M, a 30.01% increase from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. research and development expense for fiscal 2024 was $145.82M, a 91.72% increase from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. research and development expense for fiscal 2023 was $76.06M, a 7.30% increase from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. research and development expense for fiscal 2022 was $70.89M, a 133.43% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $46.60M 10-Q · filed 2026-08-04 | $115.98M 10-Q · filed 2026-08-04 | $165.91M derived: sum of 3 quarters · filed 2026-08-04 | $220.87M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $69.38M 10-Q · filed 2026-05-07 | $119.32M derived: sum of 2 quarters · filed 2026-05-07 | $174.28M derived: sum of 3 quarters · filed 2026-05-07 | $224.44M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $49.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $104.89M derived: sum of 2 quarters · filed 2026-02-24 | $155.05M derived: sum of 3 quarters · filed 2026-08-04 | $189.59M 10-K · filed 2026-02-24 |
| 2025-09-30 | $54.96M 10-Q · filed 2025-11-04 | $105.12M derived: sum of 2 quarters · filed 2026-08-04 | $139.66M 10-Q · filed 2025-11-04 | $174.33M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $50.16M 10-Q · filed 2026-08-04 | $84.70M 10-Q · filed 2026-08-04 | $119.36M derived: sum of 3 quarters · filed 2026-08-04 | $144.75M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $34.54M 10-Q · filed 2026-05-07 | $69.21M derived: sum of 2 quarters · filed 2026-05-07 | $94.59M derived: sum of 3 quarters · filed 2026-05-07 | $158.18M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $34.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $60.05M derived: sum of 2 quarters · filed 2026-02-24 | $123.64M derived: sum of 3 quarters · filed 2026-02-24 | $145.82M 10-K · filed 2026-02-24 |
| 2024-09-30 | $25.39M 10-Q · filed 2025-11-04 | $88.97M derived: sum of 2 quarters · filed 2025-11-04 | $111.16M 10-Q · filed 2025-11-04 | $141.47M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $63.58M 10-Q · filed 2025-08-05 | $85.77M 10-Q · filed 2025-08-05 | $116.08M derived: sum of 3 quarters · filed 2026-02-24 | $133.58M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $22.19M 10-Q · filed 2025-05-06 | $52.49M derived: sum of 2 quarters · filed 2026-02-24 | $69.99M derived: sum of 3 quarters · filed 2026-02-24 | $84.96M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $30.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $47.80M derived: sum of 2 quarters · filed 2026-02-24 | $62.77M derived: sum of 3 quarters · filed 2026-02-24 | $76.06M 10-K · filed 2026-02-24 |
| 2023-09-30 | $17.50M 10-Q · filed 2024-10-29 | $32.47M derived: sum of 2 quarters · filed 2024-10-29 | $45.76M 10-Q · filed 2024-10-29 | $55.85M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $14.97M 10-Q · filed 2024-08-06 | $28.26M 10-Q · filed 2024-08-06 | $38.35M derived: sum of 3 quarters · filed 2025-02-25 | $78.90M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $13.29M 10-Q · filed 2024-04-30 | $23.38M derived: sum of 2 quarters · filed 2025-02-25 | $63.93M derived: sum of 3 quarters · filed 2025-02-25 | $76.60M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $10.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $50.64M derived: sum of 2 quarters · filed 2025-02-25 | $63.31M derived: sum of 3 quarters · filed 2025-02-25 | $70.89M 10-K · filed 2025-02-25 |
| 2022-09-30 | $40.55M 10-Q · filed 2023-10-31 | $53.22M derived: sum of 2 quarters · filed 2023-10-31 | $60.79M 10-Q · filed 2023-10-31 | $68.25M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $12.67M 10-Q · filed 2023-08-01 | $20.25M 10-Q · filed 2023-08-01 | $27.70M derived: sum of 3 quarters · filed 2024-02-22 | $39.44M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $7.58M 10-Q · filed 2023-05-02 | $15.03M derived: sum of 2 quarters · filed 2024-02-22 | $26.77M derived: sum of 3 quarters · filed 2024-02-22 | $33.27M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $7.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $19.19M derived: sum of 2 quarters · filed 2024-02-22 | $25.69M derived: sum of 3 quarters · filed 2024-02-22 | $30.37M 10-K · filed 2024-02-22 |
| 2021-09-30 | $11.74M 10-Q · filed 2022-11-01 | $18.24M derived: sum of 2 quarters · filed 2022-11-01 | $22.92M 10-Q · filed 2022-11-01 | $30.54M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $6.50M 10-Q · filed 2022-08-02 | $11.18M 10-Q · filed 2022-08-02 | $18.80M derived: sum of 3 quarters · filed 2023-02-21 | $23.03M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $4.68M 10-Q · filed 2022-05-03 | $12.30M derived: sum of 2 quarters · filed 2023-02-21 | $16.53M derived: sum of 3 quarters · filed 2023-02-21 | $20.70M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $7.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $11.85M derived: sum of 2 quarters · filed 2023-02-21 | $16.02M derived: sum of 3 quarters · filed 2023-02-21 | $19.45M 10-K · filed 2023-02-21 |
| 2020-09-30 | $4.23M 10-Q · filed 2021-11-09 | $8.40M derived: sum of 2 quarters · filed 2021-11-09 | $11.83M 10-Q · filed 2021-11-09 | $19.11M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $4.17M 10-Q · filed 2021-08-10 | $7.60M 10-Q · filed 2021-08-10 | $14.88M derived: sum of 3 quarters · filed 2022-02-28 | $19.21M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $3.43M 10-Q · filed 2021-05-11 | $10.71M derived: sum of 2 quarters · filed 2022-02-28 | $15.04M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $7.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $11.61M derived: sum of 2 quarters · filed 2022-02-28 | $69.59M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $4.34M 10-Q · filed 2020-11-12 | $62.32M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |